Biofil Chemicals Surges 25.48% Amid Volatile Week Marked by Circuit Hits

2 February 2026: Upper Circuit Surge on Robust Buying Pressure

Biofil Chemicals & Pharmaceuticals Ltd opened the week with a spectacular rally, hitting the upper circuit limit of 19.99% to close at ₹42.13. The stock opened with an 11.08% gap-up and traded within a wide range of ₹36.86 to ₹42.13. The surge was accompanied by a significant volume spike of 6.23 lakh shares and a turnover of ₹2.55 crore, indicating strong investor participation beyond speculative intraday trading. Delivery volumes soared by 1191.08% compared to the five-day average, underscoring genuine accumulation.

Despite the company’s Mojo Grade of Sell and micro-cap status with a market capitalisation of ₹68 crore, the stock outperformed its Pharmaceuticals & Biotechnology sector by 20.96% while the sector declined 1.14%. The broader Sensex fell 1.03%, highlighting Biofil’s relative strength amid a weak market. Technically, the stock traded above all key moving averages, signalling robust momentum. The regulatory freeze following the upper circuit hit reflected unfilled demand and investor eagerness.

3 February 2026: Continued Buying Push Sends Stock to Another Upper Circuit

The bullish momentum extended into 3 February as Biofil Chemicals again hit the upper circuit, gaining 9.99% to close at ₹46.02. The stock traded between ₹44.00 and ₹46.34, touching the 10% upper price band limit. Trading volumes remained robust at approximately 2.05 lakh shares, with a turnover of ₹0.94 crore. Delivery volumes surged by 1023.23% compared to the five-day average, confirming sustained investor interest and accumulation.

On this day, the Pharmaceuticals & Biotechnology sector gained 2.81%, and the Sensex rose 2.63%, yet Biofil Chemicals outperformed both benchmarks with a 9.42% gain. The stock maintained its position above all key moving averages, reinforcing the strong technical uptrend. Despite the positive price action, the company’s Mojo Grade remained at Sell, reflecting ongoing fundamental challenges. The regulatory freeze at the upper circuit price again indicated unfilled demand and heightened market enthusiasm.

4 February 2026: Sharp Reversal to Lower Circuit Amid Heavy Selling

After four consecutive days of gains, Biofil Chemicals experienced a dramatic reversal on 4 February, plunging 8.26% to hit the lower circuit at ₹42.51. The stock traded within a volatile range of ₹41.71 to ₹46.34, with the weighted average price closer to the day’s low, signalling panic selling. Total traded volume was approximately 1.94 lakh shares, with delivery volumes rising 91.92% over the five-day average, indicating strong investor participation in the sell-off.

This decline contrasted sharply with the sector’s modest 0.30% gain and the Sensex’s 0.37% rise, pointing to company-specific concerns. The stock breached key support levels despite remaining above most moving averages, suggesting a shift in sentiment. The Mojo Score dropped to 34.0, maintaining a Sell rating. The heightened volatility and circuit breaker activation underscored the unsettled trading environment.

Valuation Upgrade Signals Renewed Price Attractiveness

On the same day, Biofil Chemicals announced a valuation upgrade from very attractive to attractive, reflecting improved price-to-earnings (P/E) and price-to-book value (P/BV) metrics. The stock’s P/E ratio stood at 26.09, while the P/BV was 3.49, positioning it favourably relative to peers such as Shukra Pharma, which remains very expensive. The PEG ratio was notably low at 0.06, suggesting undervaluation relative to growth prospects.

Year-to-date returns were strong at 33.87%, significantly outperforming the Sensex’s 1.74% decline. However, longer-term returns remained negative, with a 17.02% decline over one year and 47.90% over five years. Profitability metrics showed a return on equity of 13.38% but a low return on capital employed of 1.05%, indicating room for operational improvement. The valuation upgrade reflects a more compelling price proposition amid mixed fundamentals and sector challenges.

5 February 2026: Another Lower Circuit Hit Amid Panic Selling

The downtrend intensified on 5 February as Biofil Chemicals plunged 10.00% to close at ₹37.54, triggering the lower circuit breaker once again. The stock opened with a 3.21% gap down and traded between ₹37.54 and ₹40.37, with the weighted average price near the day’s low. Total volume was approximately 1.07 lakh shares, with a turnover of ₹0.41 crore, reflecting active but predominantly one-sided selling.

This steep decline far outpaced the Pharmaceuticals & Biotechnology sector’s 0.52% fall and the Sensex’s 0.41% drop, indicating company-specific distress. Despite remaining above the 5-day to 100-day moving averages, the stock fell below the 200-day average, signalling longer-term pressure. Delivery volumes increased by 58.95%, confirming strong investor conviction in the sell-off. The Mojo Grade remained at Sell with a score of 37.0, reflecting cautious analyst sentiment amid deteriorating fundamentals.

Key Takeaways

Biofil Chemicals & Pharmaceuticals Ltd’s week was characterised by extreme volatility, with two upper circuit hits early in the week followed by two lower circuit hits later, reflecting a tug-of-war between strong buying interest and panic selling. The stock’s 25.48% weekly gain significantly outperformed the Sensex’s 1.51% rise, underscoring its high momentum despite fundamental challenges.

Robust delivery volumes during the rallies indicate genuine accumulation, while elevated delivery volumes during declines suggest strong conviction in selling. The valuation upgrade to attractive status on 4 February signals improving price metrics, although profitability and capital efficiency remain modest. The company’s micro-cap status and Sell Mojo Grade advise caution amid the heightened risk and liquidity constraints.

Technically, the stock’s position above most moving averages during the rallies contrasted with breaches of longer-term support during declines, highlighting an unsettled trend. Sector and market indices remained relatively stable, indicating that Biofil’s price swings were largely company-specific.

Conclusion

Biofil Chemicals & Pharmaceuticals Ltd’s week was a study in contrasts, with sharp rallies driven by strong buying pressure and valuation improvements offset by sudden reversals and heavy selling. The stock’s ability to outperform the broader market by a wide margin reflects significant investor interest and momentum, yet the persistent volatility and fundamental cautionary signals suggest a need for careful monitoring. Investors should weigh the technical strength and valuation appeal against the risks inherent in a micro-cap stock with a Sell rating. The coming weeks will be critical in determining whether the stock can stabilise and sustain its gains or if further volatility lies ahead.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →